TP53 and B-cell chronic lymphocytic leukemia: These results together strongly suggest that PEITC was highly effective in killing p53-deficient CLL cells in vitro, and exhibited promising therapeutic activity in vivo in the TCL1-Tg:p53−/− mouse model.